A selective dopamine reuptake inhibitor improves prefrontal cortex-dependent cognitive function: Potential relevance to attention deficit hyperactivity disorder

Neuropharmacology

Volumn 64, Issue , 2013, Pages 321-328

  Schmeichel, Brooke E ^a   Zemlan, Frank P ^b   Berridge, Craig W ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b P2D Biosciences   (United States)

Author keywords

ADHD; Cognition; Dopamine; Norepinephrine; Prefrontal cortex; Psychostimulants

Indexed keywords

AHN 2005; BENZATROPINE; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; PSYCHOSTIMULANT AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; ATTENTION DEFICIT DISORDER; COGNITION; DRUG EFFICACY; DRUG MECHANISM; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; TASK PERFORMANCE; WORKING MEMORY;

ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR, ANIMAL; BENZTROPINE; COGNITION; COGNITION DISORDERS; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR FLUID; MALE; MEMORY, SHORT-TERM; NEURONS; NOOTROPIC AGENTS; NOREPINEPHRINE; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SEPTAL NUCLEI; SPATIAL BEHAVIOR;

EID: 84866423394     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2012.07.005     Document Type: Article

References (54)

1. A.F. Arnsten, and A.G. Dudley Methylphenidate improves prefrontal cortical cognitive function through alpha2 adrenoceptor and dopamine D1 receptor actions: relevance to therapeutic effects in attention deficit hyperactivity disorder Behav. Brain Funct. 1 2005 2
2. A.F. Arnsten, and S.R. Pliszka Catecholamine influences on prefrontal cortical function: relevance to treatment of attention deficit/hyperactivity disorder and related disorders Pharmacol. Biochemistry, and Behavior 99 2011 211 216
3. A.F. Arnsten Catecholamine and second messenger influences on prefrontal cortical networks of "representational knowledge": a rational bridge between genetics and the symptoms of mental illness Cereb. Cortex 17 Suppl. 1 2007 i6 15
4. A.F. Arnsten The emerging neurobiology of attention deficit hyperactivity disorder: the key role of the prefrontal association cortex J. Pediatr. 154 2009 I S43
5. C.W. Berridge, and D.M. Devilbiss Psychostimulants as cognitive enhancers: the prefrontal cortex, catecholamines, and attention-deficit/ hyperactivity disorder Biol. Psychiatry 69 2011 e101 e111
6. C.W. Berridge, and S.L. Foote Enhancement of behavioral and electroencephalographic indices of waking following stimulation of noradrenergic beta-receptors within the medial septal region of the basal forebrain J. Neurosci. 16 1996 6999 7009
7. C.W. Berridge, and J. O'Neill Differential sensitivity to the wake-promoting actions of norepinephrine within the medial preoptic area and the substantia innominata Behav. Neurosci. 115 2001 165 174
8. C.W. Berridge, and T.A. Stalnaker Relationship between low-dose amphetamine-induced arousal and extracellular norepinephrine and dopamine levels within prefrontal cortex Synapse 46 2002 140 149
9. C.W. Berridge, and K. Wifler Contrasting effects of noradrenergic beta-receptor blockade within the medial septal area on forebrain electroencephalographic and behavioral activity state in anesthetized and unanesthetized rat Neuroscience 97 2000 543 552
10. C.W. Berridge, J. O'Neil, and K. Wifler Amphetamine acts within the medial basal forebrain to initiate and maintain alert waking Neuroscience 93 1999 885 896
11. C.W. Berridge, D.M. Devilbiss, M.E. Andrzejewski, A.F. Arnsten, A.E. Kelley, B. Schmeichel, C. Hamilton, and R.C. Spencer Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function Biol. Psychiatry 60 2006 1111 1120
12. C. Berridge, J.S. Shumsky, M.E. Andrzejewski, J. McGaughy, R.C. Spencer, D. Devilbiss, and B. Waterhouse Differential sensitivity to psychostimulants across prefrontal cognitive tasks: differential involvement of Noradrenergic α1- vs. α2-receptors Biol. Psychiatry 71 2012 467 473
13. C.W. Berridge Neural substrates of psychostimulant-induced arousal Neuropsychopharmacology 31 2006 2332 2340
14. G. Bush, T.J. Spencer, J. Holmes, L.M. Shin, E.M. Valera, L.J. Seidman, N. Makris, C. Surman, M. Aleardi, E. Mick, and J. Biederman Functional magnetic resonance imaging of methylphenidate and placebo in attention-deficit/ hyperactivity disorder during the multi-source interference task Arch. Gen. Psychiatry 65 2008 102 114
15. F.P. Bymaster, J.S. Katner, D.L. Nelson, S.K. Hemrick-Luecke, P.G. Threlkeld, J.H. Heiligenstein, S.M. Morin, D.R. Gehlert, and K.W. Perry Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder Neuropsychopharmacology 27 2002 699 711
16. E. Carboni, G.L. Tanda, R. Frau, and C.G. Di Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals J. Neurochem. 55 1990 1067 1070
17. E. Carboni, A. Silvagni, C. Vacca, and C.G. Di Cumulative effect of norepinephrine and dopamine carrier blockade on extracellular dopamine increase in the nucleus accumbens shell, bed nucleus of stria terminalis and prefrontal cortex J. Neurochem. 96 2006 473 481
18. F.X. Castellanos, and R. Tannock Neuroscience of attention-deficit/ hyperactivity disorder: the search for endophenotypes Nat. Rev. Neurosci. 3 2002 617 628
19. S.R. Chamberlain, C.N. Del, J. Dowson, U. Muller, L. Clark, T.W. Robbins, and B.J. Sahakian Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder Biol. Psychiatry 62 2007 977 984
20. R.I. Desai, T.A. Kopajtic, M. Koffarnus, A.H. Newman, and J.L. Katz Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine J. Neurosci. 25 2005 1889 1893
21. D.M. Devilbiss, and C.W. Berridge Cognition-enhancing doses of methylphenidate preferentially increase prefrontal cortex neuronal responsiveness Biol. Psychiatry 64 2008 626 635
22. A. Diamond Attention-deficit disorder (attention-deficit/hyperactivity disorder without hyperactivity): a neurobiologically and behaviorally distinct disorder from attention-deficit/hyperactivity disorder (with hyperactivity) Dev. Psychopathol. 17 2005 807 825
23. R. Elliott, B.J. Sahakian, K. Matthews, A. Bannerjea, J. Rimmer, and T.W. Robbins Effects of methylphenidate on spatial working memory and planning in healthy young adults Psychopharmacology (Berl) 131 1997 196 206
24. R.A. España, and C.W. Berridge Organization of noradrenergic efferents to arousal-related basal forebrain structures J. Comp. Neurol. 496 2006 668 683
25. S.M. Florin, R. Kuczenski, and D.S. Segal Regional extracellular norepinephrine responses to amphetamine and cocaine and effects of clonidine pretreatment Brain Res. 654 1994 53 62
26. S.M. Florin, R. Kuczenski, and D.S. Segal Effects of reserpine on extracellular caudate dopamine and hippocampus norepinephrine responses to amphetamine and cocaine: mechanistic and behavioral considerations J. Pharmacol. Exp. Ther. 274 1995 231 241
27. S.L. Foote, F.E. Bloom, and G. Aston-Jones Nucleus locus ceruleus: new evidence of anatomical and physiological specificity Physiol. Rev. 63 1983 844 914
28. N.J. Gamo, M. Wang, and A.F. Arnsten Methylphenidate and atomoxetine enhance prefrontal function through alpha2-adrenergic and dopamine D1 receptors J. Am. Acad. Child. Adolesc. Psychiatry 49 2010 1011 1023
29. L.L. Greenhill Clinical effects of stimulant medication in ADHD M.V. Solanto, A.F.T. Arnsten, F.X. Castellanos, Stimulant Drugs and ADHD: Basic and Clinical Neuroscience 2001 Oxford University Press New York 31 71
30. T. Hiranita, P.L. Soto, A.H. Newman, and J.L. Katz Assessment of reinforcing effects of benztropine analogs and their effects on cocaine self-administration in rats: comparisons with monoamine uptake inhibitors J. Pharmacol. Exp. Ther. 329 2009 677 686
31. J.L. Katz, S. Izenwasser, R.H. Kline, A.C. Allen, and A.H. Newman Novel 3alpha-diphenylmethoxytropane analogs: selective dopamine uptake inhibitors with behavioral effects distinct from those of cocaine J. Pharmacol. Exp. Ther. 288 1999 302 315
32. J.L. Katz, T.A. Kopajtic, G.E. Agoston, and A.H. Newman Effects of N-substituted analogs of benztropine: diminished cocaine-like effects in dopamine transporter ligands J. Pharmacol. Exp. Ther. 309 2004 650 660
33. R.P. Kesner, G. Farnsworth, and B.V. DiMattia Double dissociation of egocentric and allocentric space following medial prefrontal and parietal cortex lesions in the rat Behav. Neurosci. 103 1989 956 961
34. R. Kuczenski, D.S. Segal, A.K. Cho, and W. Melega Hippocampus norepinephrine, caudate dopamine and serotonin, and behavioral responses to the stereoisomers of amphetamine and methamphetamine J. Neurosci. 15 1995 1308 1317
35. R. Kuczenski, W.P. Melega, A.K. Cho, and D.S. Segal Extracellular dopamine and amphetamine after systemic amphetamine administration: comparison to the behavioral response J. Pharmacol. Exp. Ther. 282 1997 591 596
36. M.D. Lapiz, and D.A. Morilak Noradrenergic modulation of cognitive function in rat medial prefrontal cortex as measured by attentional set shifting capability Neuroscience 137 2006 1039 1049
37. S.M. Li, A.H. Newman, and J.L. Katz Place conditioning and locomotor effects of N-substituted, 4′,4′-difluorobenztropine analogs in rats J. Pharmacol. Exp. Ther. 313 2005 1223 1230
38. C.J. Loland, R.I. Desai, M.F. Zou, J. Cao, P. Grundt, K. Gerstbrein, H.H. Sitte, A.H. Newman, J.L. Katz, and U. Gether Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors Mol. Pharmacol. 73 2008 813 823
39. M.A. Mehta, B.J. Sahakian, and T.W. Robbins Comparative psycholpharmacology of methylphenidate and related drugs in human volunteers, patients with ADHD, and experimental animals M.V. Solanto, A.F.T. Arnsten, F.X. Castellanos, Stimulant Drugs and ADHD: Basic and Clinical Neuroscience 2001 Oxford University Press New York 303 331
40. M.A. Mehta, I.M. Goodyer, and B.J. Sahakian Methylphenidate improves working memory and set-shifting in AD/HD: relationships to baseline memory capacity J. Child Psychol. Psychiatry 45 2004 293 305
41. K.C. Pang, X. Jiao, S. Sinha, K.D. Beck, and R.J. Servatius Damage of GABAergic neurons in the medial septum impairs spatial working memory and extinction of active avoidance: effects on proactive interference Hippocampus 21 2011 835 846
42. S. Raje, J. Cornish, A.H. Newman, J. Cao, J.L. Katz, and N.D. Eddington Pharmacodynamic assessment of the benztropine analogues AHN-1055 and AHN-2005 using intracerebral microdialysis to evaluate brain dopamine levels and pharmacokinetic/pharmacodynamic modeling Pharm. Res. 22 2005 603 612
43. J.L. Rapoport, and G. Inoff-Germain Responses to methylphenidate in attention-deficit/hyperactivity disorder and normal children: update 2002 J. Attention. Disord. 6 2002 S57 S60
44. T.W. Robbins, and A.F. Arnsten The neuropsychopharmacology of fronto-executive function: monoaminergic modulation Annu. Rev. Neurosci. 32 2009 267 287
45. S.R. Sesack, V.A. Hawrylak, C. Matus, M.A. Guido, and A.I. Levey Dopamine axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse immunoreactivity for the dopamine transporter J. Neurosci. 18 1998 2697 2708
46. H.R. Smith, and K.C. Pang Orexin-saporin lesions of the medial septum impair spatial memory Neuroscience 132 2005 261 271
47. M.V. Solanto Attention-deficit/hyperactivity disorder M.V. Solanto, A.F.T. Arnsten, F.X. Castellanos, Stimulant Drugs and ADHD: Basic and Clinical Neuroscience 2001 Oxford University Press New York 3 30
48. R.C. Spencer, R. Klein, and C.W. Berridge Psychostimulants act within the prefrontal cortex to improve cognition function Biol. Psychiatry 72 2012 221 227
49. D.C. Turner, A.D. Blackwell, J.H. Dowson, A. McLean, and B.J. Sahakian Neurocognitive effects of methylphenidate in adult attention-deficit/ hyperactivity disorder Psychopharmacology (Berl) 178 2005 286 295
50. C.J. Vaidya, G. Austin, G. Kirkorian, H.W. Ridlehuber, J.E. Desmond, G.H. Glover, and J.D.E. Gabrieli Selective effects of methylphenidate in attention deficit hyperactivity disorder: a functional magnetic resonance study Proc. Natl. Acad. Sci. U S A 95 1998 14494 14499
51. T.E. Wilens, S.V. Faraone, and J. Biederman Attention-deficit/ hyperactivity disorder in adults JAMA 292 2004 619 623
52. W.L. Woolverton, J.K. Rowlett, K.M. Wilcox, I.A. Paul, R.H. Kline, A.H. Newman, and J.L. Katz 3′- and 4′-chloro-substituted analogs of benztropine: intravenous self-administration and in vitro radioligand binding studies in rhesus monkeys Psychopharmacology (Berl) 147 2000 426 435
53. W.L. Woolverton, G.S. Hecht, G.E. Agoston, J.L. Katz, and A.H. Newman Further studies of the reinforcing effects of benztropine analogs in rhesus monkeys Psychopharmacology (Berl) 154 2001 375 382
54. B.K. Yamamoto, and S. Novotney Regulation of extracellular dopamine by the norepinephrine transporter J. Neurochem. 71 1998 274 280